Aditxt (NASDAQ: ADTX) recently partnered with Premier Medical Laboratory Services to provide individuals with personalized information regarding their immune system via the AditxtScore(TM). A recent article reads: “The AditxtScore can be used to provide those tested with important answers to questions like: Are antibodies present? How are these antibodies present – vaccine or natural immune system response? Will this immunity status provide protection from the virus in the future? What is the best approach to creating immunity for that individual?” Regarding the partnership, Kevin Murdock, CEO of Premier Medical Laboratory Services, commented, “As new variants emerge, we want to equip physicians with the most advanced tests that allow a comprehensive view of their patient’s health status. With AditxtScore, individuals can make more informed decisions about whether vaccination, boosters or other risk mitigation strategies are the right course of action for them.”
To view the full article, visit https://ibn.fm/R5Zzd
About Aditxt Inc.
Aditxt is a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system. Aditxt’s immune monitoring technologies are designed to provide a personalized immune profile. Aditxt’s immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases and allergies. For more information, please visit www.Aditxt.com and www.AditxtScore.com.
NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork
HealthLynked (OTCQB: HLYK) has completed a reverse stock split as part of its strategy to…
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases, announced the publication of…
Clene (NASDAQ: CLNN), through its wholly owned subsidiary Clene Nanomedicine Inc., announced new preclinical data…
Oncotelic Therapeutics (OTCQB: OTLC), a clinical-stage biopharmaceutical company developing oncology and immunotherapy treatments, provided an…
Fifty 1 Labs (OTC: FITY) through its subsidiary Fifty1 AI Labs, announced the publication of…
Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company developing the IzoView Breast…